Osteogenic potential of a biomaterial enriched with osteostatin and mesenchymal stem cells in osteoporotic rabbits

Mesoporous bioactive glasses (MBGs) of the SiO2–CaO–P2O5 system are biocompatible materials with a quick and effective in vitro and in vivo bioactive response. MBGs can be enhanced by including therapeutically active ions in their composition, by hosting osteogenic molecules within their mesopores,...

Descripción completa

Detalles Bibliográficos
Autores: Luengo Alonso, Gonzalo, Bravo Giménez, Beatriz, Lozano Borregón, Daniel, Heras, Clara, Sánchez Salcedo, Sandra, Benito Garzón, Lorena, Abella García, Mónica, Vallet Regí, María Dulce Nombre, Cecilia López, David, Salinas Sánchez, Antonio Jesús
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/104696
Acceso en línea:https://hdl.handle.net/20.500.14352/104696
Access Level:acceso abierto
Palabra clave:615.46
577.2
Zinc-containing MBGs
Osteostatin
Mesenchymal stem cells
Bone regeneration
Osteoporotic rabbits
Biología molecular (Química)
3314 Tecnología Médica
Descripción
Sumario:Mesoporous bioactive glasses (MBGs) of the SiO2–CaO–P2O5 system are biocompatible materials with a quick and effective in vitro and in vivo bioactive response. MBGs can be enhanced by including therapeutically active ions in their composition, by hosting osteogenic molecules within their mesopores, or by decorating their surfaces with mesenchymal stem cells (MSCs). In previous studies, our group showed that MBGs, ZnO-enriched and loaded with the osteogenic peptide osteostatin (OST), and MSCs exhibited osteogenic features under in vitro conditions. The aim of the present study was to evaluate bone repair capability after large bone defect treatment in distal femur osteoporotic rabbits using MBGs (76%SiO2–15%CaO–5%P2O5–4%ZnO (mol-%)) before and after loading with OST and MSCs from a donor rabbit. MSCs presence and/or OST in scaffolds significantly improved bone repair capacity at 6 and 12 weeks, as confirmed by variations observed in trabecular and cortical bone parameters obtained by micro-CT as well as histological analysis results. A greater effect was observed when OST and MSCs were combined. These findings may indicate the great potential for treating critical bone defects by combining MBGs with MSCs and osteogenic peptides such as OST, with good prospects for translation to clinical practice.